Karya
Judul/Title The potency of Pentagamavunone-0 (PGV-0) as chemopreventive agent for the formation and growth of breast cancer as revealed in 3D model
Penulis/Author Wulandari (1); Dr. apt. Muthi' Ikawati, M.Sc. (2); Prof. Dr. apt. Edy Meiyanto, M.Si. (3)
Tanggal/Date 6 2020
Kata Kunci/Keyword
Abstrak/Abstract Pentagamavunone-0 (PGV-0) or 2,5-bis(4'-hydroxy-3-methoxybenzylidine)-cyclopentanone is a curcumin analogue that exhibits anticancer activity in breast cancer cells. However, most of previous reports are limited to the use of two-dimensional (2D) cell culture. The use of three-dimensional (3D) cell culture model in cancer research can represent the real condition of cancer growth in patients better than the 2D culture. The purpose of this study was to determine the anticancer activity of PGV-0 on a 3D model of HCC 1954 breast cancer cells. HCC 1954 cells were grown in the 3D culture in the presence of PGV-0, and the spheroid formation and growth of formed spheroids were observed using a microscope at 24 and 96 h, respectively. PGV-0 inhibited the formation and growth of spheroids at the concentration as low as 60 µM. The cytotoxic effect of PGV-0 appeared in a dose-dependent manner with the IC50 value of 70.9 µM. The results of this study indicate that PGV-0 has anticancer activity on a 3D model of HCC 1954 breast cancer cell line. Therefore, it can be used as a candidate for cancer chemopreventive agent.
Rumpun Ilmu Analisis Farmasi dan Kimia Medisinal
Bahasa Asli/Original Language English
Level Internasional
Status
Dokumen Karya
No Judul Tipe Dokumen Aksi
12020-Wulandari et al-IJBiotech.pdf[PAK] Full Dokumen
220200603-LoA Wulandari_Prof Edy-IJBiotech.pdfBukti Accepted
3b_ IJBiotech-Editorial team.pdf[PAK] Halaman Editorial
4a_ IJBiotech 25(1)-cover.pdf[PAK] Halaman Cover
5h_ IJBiotech-Scopus and SJR.pdf
6c_ IJBiotech 25(1)-table of content.pdf[PAK] Daftar Isi
7e_ Wulandari et al-IJBiotech 2020-similarity Turnitin14%.pdf[PAK] Cek Similarity
8f_ IJBiotech-author correspondence and review.pdf[PAK] Bukti Korespondensi Penulis
9g_ Wulandari et al 2020-IJBiotech-LoA.pdfBukti Accepted
10i_ Wulandari et al 2020-IJBiotech-Scopus.pdf